SELLAS Life Sciences Prices $172.5 Million Public Offering to Fund Clinical Pipeline
SELLAS Life Sciences Group (SLS) prices an underwritten public offering of common stock at $13.00 per share, raising $172.5 million to advance cancer therapies.
ALFAFINDER USA News
Straight from the SEC filing
Every SEC filing by SELLAS Life Sciences Group, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (20 Nov 2026). Not a valuation or a recommendation.
Up 12.5% over the last month ($12.14 on 21 Oct → $13.66 on 20 Nov). Daily closing prices. Source: Yahoo Finance.
| 21 Oct | $12.14 |
|---|---|
| 22 Oct | $11.35 |
| 23 Oct | $11.54 |
| 26 Oct | $11.34 |
| 27 Oct | $12.17 |
| 28 Oct | $10.38 |
| 29 Oct | $10.16 |
| 30 Oct | $9.68 |
| 2 Nov | $8.55 |
| 3 Nov | $8.87 |
| 4 Nov | $9.14 |
| 5 Nov | $7.88 |
| 6 Nov | $8.42 |
| 9 Nov | $8.58 |
| 10 Nov | $8.37 |
| 11 Nov | $8.42 |
| 12 Nov | $8.03 |
| 13 Nov | $7.86 |
| 16 Nov | $7.47 |
| 17 Nov | $19.15 |
| 18 Nov | $17.95 |
| 19 Nov | $14.86 |
| 20 Nov | $13.66 |
SELLAS Life Sciences Group (SLS) prices an underwritten public offering of common stock at $13.00 per share, raising $172.5 million to advance cancer therapies.
SELLAS Life Sciences (SLS) announces positive Phase 3 REGAL trial results for GPS in AML, showing a 41% reduction in risk of death and 24.0 month median survival.
Track SELLAS Life Sciences Group, Inc. live
Get the next SELLAS Life Sciences Group, Inc. SEC filing seconds after it lands.